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Abstract
Background: Breast and prostate cancer are two commonly diagnosed cancers in the United States. Prior work
suggests that cancer causing genes and cancer susceptibility genes can be identified.
Methods: We conducted a genome-wide association study (Affymetrix 100K SNP GeneChip) of cancer in the
community-based Framingham Heart Study. We report on 2 cancer traits – prostate cancer and breast cancer –
in up to 1335 participants from 330 families (54% women, mean entry age 33 years). Multivariable-adjusted
residuals, computed using Cox proportional hazards models, were tested for association with qualifying SNPs (70,
987 autosomal SNPs with genotypic call rate ≥80%, minor allele frequency ≥10%, Hardy-Weinberg test p ≥ 0.001)
using generalized estimating equations (GEE) models and family based association tests (FBAT).
Results: There were 58 women with breast cancer and 59 men with prostate cancer. No SNP associations
attained genome-wide significance. The top SNP associations in GEE models for each trait were as follows: breast
cancer, rs2075555, p = 8.0 × 10-8 in COL1A1; and prostate cancer, rs9311171, p = 1.75 × 10-6 in CTDSPL. In analysis
of selected candidate cancer susceptibility genes, two MSR1 SNPs (rs9325782, GEE p = 0.008 and rs2410373,
FBAT p = 0.021) were associated with prostate cancer and three ERBB4 SNPs (rs905883 GEE p = 0.0002,
rs7564590 GEE p = 0.003, rs7558615 GEE p = 0.0078) were associated with breast cancer. The previously
reported risk SNP for prostate cancer, rs1447295, was not included on the 100K chip. Results of cancer
phenotype-genotype associations for all autosomal SNPs are web posted at http://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?id=phs000007.
Conclusion: Although no association attained genome-wide significance, several interesting associations
emerged for breast and prostate cancer. These findings can serve as a resource for replication in other
populations to identify novel biologic pathways contributing to cancer susceptibility.
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Breast and prostate cancer are the most frequently diag-
nosed cancers in women and men respectively with over
200,000 cases each of new breast and prostate cancer esti-
mated for 2006 in the United States [1]. Furthermore,
prostate cancer is the second leading cause of cancer-
related deaths in men and breast cancer is the second lead-
ing cause of cancer-related deaths in women. Family his-
tory is a well established risk factor for both breast and
prostate cancer providing evidence for underlying genetic
factors contributing to cancer occurrence. Accumulating
research has identified a number of candidate genes and
biologic pathways associated with increased susceptibility
to cancer. However, even the most penetrant mutations,
such as in BRCA1 and BRCA2, account for only 5–10% of
cases and are present in <1% of the general population.
Genome-wide association studies (GWAS) provide a com-
prehensive approach to identification of genetic variants
associated with cancer risk unconstrained by existing
knowledge and may permit detection of common genetic
variants each with small associated cancer risk but great
public health impact. Reports from two recent GWAS
demonstrated the importance of this approach with the
discovery of novel loci for breast cancer susceptibility
[2,3]. Four SNPs in the FGFR2 gene were strongly associ-
ated with breast cancer and the association was confirmed
in a sample of cases and controls derived from three addi-
tional studies [3].
We used the Framingham Heart Study (FHS) Affymetrix
100K SNP genotyping resource for GWAS of breast and
prostate cancer phenotypes. The FHS offers the advantage
of a prospective longitudinal family-based community
sample with participants who have been well-character-
ized throughout adulthood with respect to risk factors and
diseases, including cancer. We report results of two com-
plementary strategies to identify genome-wide associa-
tions with cancer phenotypes: 1) a simple low p-value
SNP ranking strategy; and 2) 100K SNP associations
within candidate genes and regions previously reported to
be associated with these cancers in humans.
Methods
Study sample
The genotyped study sample comprised 1345 Original
cohort (n = 258) and Offspring (n = 1087) participants
from the 330 largest FHS families. The Overview [4] pro-
vides further details of this sample. There were 250 partic-
ipants in the sample with cancer (excluding non-
melanoma skin cancer) including 58 women with breast
cancer, and 59 men with prostate cancer. The Boston Uni-
versity Medical Center Institutional Review Board
approved the examination content of Original Cohort
and Offspring examinations. All participants provided
written informed consent including consent for genetic
studies.
Cancer phenotype definitions and residual creation
The 5209 Original Cohort participants have been exam-
ined biennially since study inception in 1948 and the
5124 Offspring Cohort participants (children of the Orig-
inal Cohort and spouses of the children) have been exam-
ined approximately every 4 years since enrollment in
1971. Cancer cases were identified at routine examina-
tions or by health-history updates for participants who
did not attend an examination. Medical records were
reviewed by two independent reviewers (BEK, GLS). The
vast majority of cancers were confirmed by pathology
reports; <3.4% of cancer cases were based on death certif-
icate or clinical diagnosis alone. The 1976 World Health
Organization ICD-O coding was used to classify all pri-
mary cancers. Hence, topography, location (subdivision
of site), histology or morphology (cell histopathology),
behavior (degree of malignancy), and grade (histological
grading & differentiation) were recorded along with date
of diagnosis. Cancer cases reviewed through December
31, 2005 were included in this study. The proportion of
women and men in the study sample with breast (8%)
and prostate cancer (9%) respectively was similar to that
in the full FHS sample.
Cox proportional hazards models were used to generate
martingale residuals using the PHREG procedure in SAS
to perform the regression analysis of time from study
entry to cancer diagnosis or last contact free of cancer.
Breast cancer was examined in women only and models
were cohort-specific and adjusted for 1) age at entry and
2) age, parity, and body mass index at study entry. For
prostate cancer, in men only, models were cohort-specific
and adjusted for age at entry.
Genotyping
Affymetrix 100K SNP GeneChip genotyping and the
Marshfield STR genotyping performed by the Mammalian
Genotyping Service http://research.marshfieldclinic.org/
genetics are described in the Overview [4]. SNPs were
excluded if minor allele frequency <0.10 (n = 38062);
genotypic call rate <0.80 (n = 2346); Hardy Weinberg
equilibrium test p < 0.001 (n = 1595). There were 70,987
autosomal SNPs available for analysis after the exclusions.
Statistical Analysis
The statistical methods for genome-wide association anal-
yses are described in detail in the Overview [4]. While
there are various suggested methods for interpretation of
genome-wide significance, we chose to use a conservative
(p < 0.05/10-6 = 5 × 10-8) threshold to define genome-
wide significance for this report.Page 2 of 10
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All cancer residual traits listed in Table 1 were computed
using Cox proportional hazards models. The full set of
FHS participants with the phenotype were used to create
the residuals. The residuals were used to test for associa-
tion between the genotyped subset of participants and the
SNPs using family-based association test (FBAT) and gen-
eralized estimating equation (GEE) models. FBAT analy-
ses were restricted to at least 10 informative families. The
GEE tests tended to give an excess of very small p-values
over what would be expected (see Overview [4]).
SNP prioritization
We used several strategies to prioritize SNPs associated
with cancer traits. First, we used an untargeted approach
whereby SNP associations were ranked according to the
strength of the p-value for each trait. Next we identified
candidate genes reported to be associated with each can-
cer trait from review of the literature. Candidate genes
were selected by searching PubMed (using susceptibility,
gene, cancer and (breast or prostate) as keywords, last
accessed 08-15-06), and the Entrez Gene and Online
Mendelian Inheritance in Man resources, as well as recent
text books. All available 100K SNPs in or near the a priori
selected candidate genes were investigated for association
with cancer traits. Finally for prostate cancer, we also
examined SNP associations in the region on chromosome
8 (8q24) previously reported to be associated with pros-
tate cancer in Icelandic families and confirmed in three
case-control series [5] and African American men [6]. Fur-
ther, for prostate cancer we examined the overlap in SNP
associations in our study and the top 500 ranked SNPs
from the Cancer Genetics Markers of Susceptibility
(CGEMS) project sponsored by the National Cancer Insti-
tute. Because CGEMS used an Illumina platform for gen-
otyping and the genotyping used in this study was
performed with an Affymetrix platform, the gene_symbol
from the UCSC annotation was used to link with CGEMS
top 500 SNP list. Using this method, 1487 SNPs in FHS
100K (including SNPs with MAF < 0.1) correlated with the
CGEMS top 500 SNPs related to a known gene.
SNPs were annotated with the UCSC genome browser
tables using the May 2004 assembly http://
genome.ucsc.edu/[7,8]. All genes within 60 kb of the top
ranked SNPs were identified. The physical location of the
SNPs was based on Build 35 of Genome for this report;
however, the 100K web browser was based on Build 36.
Results
The cancer phenotypes available in the FHS 100K SNP
resource, including details of the sample size, number of
cancer events, and covariate adjustment for each trait are
listed in Table 1. In this report, we consider only two phe-
notypes: breast cancer in women (multivariable-adjusted)
and prostate cancer in men. Among participants in the
100K sample the mean age at breast cancer diagnosis was
59 years (range 35 to 83 years) in Offspring Cohort
women and 70 years (range 35 to 97 years) in Original
Cohort women; the mean age at prostate cancer diagnosis
was 66 years (range 43 to 85 years) in Offspring Cohort
men and 76 years (range 53 to 95 years) in Original
Cohort men.
For each of the cancer phenotypes, Table 2 provides the
top 15 SNPs ranked in order by lowest p-value for the GEE
models and for the FBAT models (all SNP associations can
be viewed on the web) [9]. None of the SNP associations
achieved genome-wide significance (p < 5 × 10-8) [4].
However, for prostate cancer, the top SNP in GEE models,
rs9311171, is in CTDSPL (CTD {carboxy-terminal
domain, RNA polymerase II, polypeptide A} small phos-
phatase-like), a gene that may play a role in tumor sup-
pression [10].
Table 1: Cancer Phenotypes for the Framingham Heart Study 100K Analyses
Phenotype* Traits Number of 
participants
Events Adjustment (database phenotype variable name)
All Cancer* (excluding 
non-melanoma skin cancer)
2 1335 250 Cohort- and sex-specific
1. age at study entry (allcancer1)
2. multivariable adjusted for age, body mass index, and cigarette smoking at 
study entry (allcancer2)
Breast Cancer (women) 2 723 58 Cohort-specific
1. age at study entry (breastcancer1)
2. multivariable adjusted for age, parity, and body mass index at study entry 
(breastcancer2)
Prostate Cancer (men) 1 617 59 Cohort-specific
1. age at study entry (prostatecancer1)
Residuals from these models were used as traits to test for association with SNP genotypes. All residuals created using Cox Proportional Hazards 
regression. Cancers ascertained through December 31, 2005
*All SNP associations for all phenotypes in the table including all cancer are available on the web http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?id=phs000007Page 3 of 10
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Table 2 that were of interest. For prostate cancer, in GEE
models rs906304 (rank 27, p = 0.000067), is in NCOR2
also known as SMRT. SMRT levels have been reported to
be elevated in prostate cancer cells, and result in suppres-
sion of anti-proliferative target gene actions for the vita-
min D receptor [11,12]. In FBAT models, for prostate
cancer SNP rs255561 (rank 17, p = 0.00039), is near
XRCC4, a gene that plays a role in DNA repair and
rs1897676 (rank 50, p = 0.0012), is in PTPRD. Protein
tyrosine phosphatases are signaling molecules involved in
the regulation of a variety of cellular processes including
cell growth, differentiation, mitotic cycle, and oncogenic
transformation [13]. For breast cancer in GEE models
rs4146372 (rank 31, p = 0.00007), is near RAB21, SNP
rs9307561 (rank 40, p = 0.0001), is near FAT4, and
rs10512849 (rank 46, p = 0.00014), is in FGF10. These
genes appear to play biologic roles in a variety of processes
including tumor growth and suppression [13,14]. In FBAT
models, for breast cancer rs2836391 (rank 46, p =
0.0012), is in ERG, an oncogene important in the devel-
opment of prostate cancer [15,16].
Our second strategy was to identify from the literature
candidate genes implicated in breast and prostate cancer
susceptibility (see Additional data file 1). For prostate can-
cer, we identified 63 candidate genes. Twenty of these can-
didate genes had from 1 to 20 SNPs on the 100K chip
whereas the remaining genes had no SNP coverage on the
chip. For breast cancer, 75 potential candidate genes were
identified, 28 of these genes had between 1 and 35 SNPs
on the 100K chip and the remaining candidate genes were
not covered on the chip. Two SNPs in MSR1 (rs9325782,
GEE p = 0.008 and rs2410373, FBAT p = 0.021) were asso-
ciated with prostate cancer and three SNPs in ERBB4
(rs905883 GEE p = 0.0002, rs7564590 GEE p = 0.003,
rs7558615 GEE p = 0.0078) were associated with breast
cancer (Table 3). For prostate cancer, a region on chromo-
some 8q24 was recently reported to be associated with
prostate cancer risk in Icelandic men and confirmed in
three case-control series of men of European ancestry and
African American men [5,6]. There were a total of 64 SNPs
on the 100K chip in this 8q24 region (128 to 129.3 Mb
interval). However, the reported risk SNP, rs1447295, was
not included on the 100K chip and none of the 64 availa-
ble SNPs were in linkage disequilibrium with the risk
SNP. Five other SNPs in this region were associated with
prostate cancer with a GEE or FBAT p-value < 0.01 (Table
4).
The National Cancer Institute commenced the CGEMS
[17] initiative to conduct genome-wide association stud-
ies to identify genetic factors related to prostate and breast
cancer. We examined overlap between the top 500 ranked
SNPs for prostate cancer in CGEMS phase 1a [18] and the
results of the FHS 100K GWAS analysis for prostate can-
cer. The physical position of the SNP was used to detect
overlapping associations and the results are shown in
Table 5. Of note, many of the associations in Table 5 are
in SNPs with very low minor allele frequencies and the
results are presented according to minor allele frequency.
WWOX gene, a tumor suppressor gene, that has been
reported to play a role in prostate cancer [19], showed evi-
dence of association (rs3751832, p = 0.0009) in our study
sample.
Discussion
Breast and prostate cancer are the two most frequently
diagnosed cancers in the United States and result in sub-
stantial morbidity and mortality [1]. A number of breast
and prostate cancer susceptibility genes and chromo-
somal regions have been identified [2,3,5,20-34]. How-
ever, currently known genes account for only a fraction of
the familial aggregation of breast cancer [25] and few
prostate cancer susceptibility genes have even been identi-
fied. Risk for these cancers is likely mediated through var-
iation in many genes, each conferring a relatively small
risk for the disease. Genome-wide association studies pro-
vide an opportunity to discover novel genes and pathways
that play a causal role in cancer occurrence and in turn
may lead to new therapies for the prevention and treat-
ment of cancer. Finding genetic associations with breast
and prostate cancer risk that are robust across multiple
studies may facilitate the identification of high risk indi-
viduals who can be targeted for early screening and pre-
ventive interventions.
We report GWAS results for breast cancer and prostate
cancer phenotypes in a community-based sample of
adults from two generations of the same families.
Although none of the SNP associations achieved genome-
wide significance in GEE or FBAT models, this resource
has the potential to detect novel cancer susceptibility
genes and to explore the relevance of promising candidate
gene associations to human cancer. Our results can be
compared to those from other genome-wide association
studies such as the National Cancer Institute's CGEMS
[17]. Although the two studies used different genotyping
platforms limiting overlap in the SNPs examined, we were
able to determine the physical position of the SNPs. Using
this strategy, SNPs in the ERRB4 gene (CGEMS DSSNP_ID
rs2371438 and FHS 100K SNP rs10497958) were associ-
ated with prostate cancer. ErbB proteins are widely
expressed in prostate cells [35] and may play a role in
tumor development, growth and progression in human
prostate cancer [36,37]. We also examined the 8q24
region previously associated with prostate cancer risk.
CGEMS investigators recently reported a second inde-
pendent risk SNP (rs6983267) within the 8q24 strongly
associated with prostate cancer [34]. The Affymetrix 100KPage 4 of 10
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2a. GEE results ranked by p-value
SNP Chr Physical Position GEE p-value FBAT p-value Gene region 
(within 60 kb)
BREAST CANCER
rs2075555 17 45,629,290 8.3 × 10-8 0.157 COL1A1
rs6556756 5 163,821,858 5.0 × 10-7 0.114
rs1154865 12 72,276,104 6.6 × 10-7 0.052
rs1978503 18 51,815,280 9.66 × 10-7 0.287
rs1926657 13 94,672,957 1.9 × 10-6 0.072 ABCC4
rs10263639 7 66,503,417 2.7 × 10-6 0.590
rs10490113 2 59,410,998 4.7 × 10-6 0.077
rs458685 21 30,099,382 6.0 × 10-6 0.064 GRIK1
rs1876206 15 46,687,878 6.0 × 10-6 0.742 FBN1
rs9314033 5 163,822,784 1.2 × 10-5 0.058
rs10486490 7 25,846,789 1.3 × 10-5 0.245
rs9325024 5 146,185,979 1.7 × 10-5 0.112 PPP2R2B
rs1294255 1 229,808,093 1.9 × 10-5 0.470
rs10513754 3 178,681,862 2.8 × 10-5 0.189
rs10501093 11 27,946,695 3.0 × 10-5 0.066 KIF18A
PROSTATE CANCER
rs9311171 3 37,971,481 1.8 × 10-6 0.392 CTDSPL
rs1529276 13 102,726,008 1.8 × 10-6 0.071
rs10498792 6 51,774,590 3.0 × 10-6 0.285 PKHD1
rs4466137 5 83,021,495 3.1 × 10-6 0.305 HAPLN1
rs345013 3 146,656,486 5.1 × 10-6 0.002
rs10505137 8 111,210,785 1.3 × 10-5 0.002
rs1873038 3 175,020,343 1.8 × 10-5 0.317 NLGN1
rs8019932 14 29,676,177 1.9 × 10-5 0.019
rs344985 3 146,619,475 2.1 × 10-5 0.002
rs1920676 11 15,789,323 2.2 × 10-5 0.196
rs10511206 10 127,209,365 2.4 × 10-5 0.028
rs1037569 5 119,954,204 2.8 × 10-5 0.165
rs2109312 2 128,292,061 3.0 × 10-5 0.786 WDR33
rs1352416 3 174,963,409 3.4 × 10-5 0.201 NLGN1
rs1440714 11 15,,790,399 3.7 × 10-5 0.223
2b. FBAT results ranked by p-value
SNP Chr Physical Position GEE p-value FBAT p-value Gene Region 
(within 60 kb)
BREAST CANCER
rs7711990 5 180,307,504 0.010 8.4 × 10-5
rs1451125 4 137,449,995 0.008 9.5 × 10-5
rs4266352 4 109,823,951 0.001 1.2 × 10-4
rs6720918 2 122,873,276 0.027 1.9 × 10-4
rs6101183 20 59,025,355 0.132 2.0 × 10-4
rs9307064 4 90,503,827 0.159 2.2 × 10-4
rs10512287 9 101,538,523 0.807 2.3 × 10-4 GRIN3A
rs7190881 16 7,368,424 0.475 2.9 × 10-4
rs2224402 1 229,359,076 0.418 3.1 × 10-4 C1orf57
rs10516690 4 84,822,792 0.954 3.7 × 10-4
rs10487920 7 145,895,727 0.085 3.9 × 10-4 CNTNAP2
rs6479347 9 91,348,121 0.017 4.5 × 10-4Page 5 of 10
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reported risk SNPs; however, we did identify five other
SNPs in this region associated with prostate cancer. The
underlying biologic mechanism mediating prostate can-
cer risk associated with the SNPs and chromosomal region
remains unknown. A two-stage approach, genome-wide
association followed by selective genotyping of SNPs with
suggestive evidence of association, may provide an effi-
cient strategy for pursuing initial genome-wide results
[2,38,39].
Several important limitations merit comment. First, this
study used cancer cases identified through surveillance of
a multigenerational community-based sample. The
enrollment and examination of Original Cohort and Off-
spring Cohort participants began years before DNA collec-
tion occurred. Thus, a survival bias may have been
introduced. Our cases may be comprised of early-staged
and less lethal cancers. To address this potential bias, we
adjusted for covariates using the full Framingham sample,
and used the residual traits for the subset of individuals
genotyped using the 100K Affymetrix GeneChip to test for
association with the SNPs in linear regression models.
Residual traits from Cox models typically are not ideally
distributed for linear regression models, but our adjust-
ment method using the full Framingham sample pre-
cludes the testing of SNP associations with cancer traits
using Cox models. Second, we had a small number of can-
cer events (250 all cancer cases, 58 breast cancer cases and
59 prostate cancer cases) limiting our ability to detect SNP
associations. In a recent small GWAS of age-related macu-
lar degeneration that included 96 cases and 50 controls,
an association with the CFH gene was identified [40] and
confirmed in larger studies [41-43]. However, in that
report, individuals homozygous for the CFH risk allele
had a sevenfold increased likelihood of age-related macu-
lar degeneration [40]. It is very unlikely that common
genetic variants for cancer phenotypes will confer a risk
for cancer susceptibility of that magnitude. For example,
the odds ratio associated with the risk marker identified
Table 3: All SNP Associations within Selected Breast and Prostate Candidate Genes (up to 60 kb)
Associations within Candidate Genes Selected by Cancer Type: FBAT or GEE p-value < 0.01
Cancer Trait Gene SNP Chr Physical 
Position
GEE p-value FBAT p-value
Breast cancer ERBB4 rs905883 2 213,013,976 2.0 × 10-4 0.8517
Breast cancer ERBB4 rs7564590 2 213,213,406 0.0032 0.2567
Breast cancer ERBB4 rs7558615 2 212,771,655 0.008 0.8457
Prostate cancer MSR1 rs9325782 8 16,134,844 8.2 × 10-4 0.3448
Prostate cancer MSR1 rs2410373 8 15,968,877 0.014 0.02051
rs1924587 13 96,195,380 0.020 4.6 × 10-4 HS6ST3
rs2059273 16 5,991,144 0.005 4.9 × 10-4 A2BP1
rs2822669 21 14,752,449 0.029 5.7 × 10-4 SAMSN1
PROSTATE CANCER
rs657057 6 56,402,241 0.109 3.4 × 10-5 DST
rs6691482 1 170,274,521 0.007 4.0 × 10-5 SLC9A11
rs4378061 9 10,930,127 0.633 6.6 × 10-5
rs2056387 1 234,250,153 0.159 1.1 × 10-4 RYR2
rs2274626 1 176,253,589 0.005 1.4 × 10-4 NPHS2
rs181247 17 53,562,730 0.552 3.2 × 10-4 OR4D1|OR4D2
rs7827348 8 3,020,222 0.054 3.6 × 10-4
rs255561 5 82,386,566 0.040 3.9 × 10-4 XRCC4
rs1504858 4 137,063,555 0.010 3.9 × 10-4
rs954709 4 167,317,424 0.049 4.2 × 10-4
rs2179443 20 37,450,516 0.057 4.4 × 10-4
rs35239 5 68,064,834 0.657 4.6 × 10-4
rs477516 8 16,758,362 0.057 5.1 × 10-4
rs595725 1 28,993,331 0.239 5.3 × 10-4 OPRD1
rs10515322 5 101,539,543 0.051 5.4 × 10-4 SLCO4C1
*Autosomal SNPs with genotypic call rate ≥80%, minor allele frequency ≥10%, Hardy-Weinberg test p ≥ 0.001, and ≥10 informative families for 
FBAT. The physical location of the SNPs was based on Build 35 of Genome; however, the 100K web browser was based on Build 36
Table 2: Cancer Phenotypes for FHS 100K Project: Results of Association Analyses* (Continued)Page 6 of 10
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bined Icelandic sample [5]. Furthermore, the associations
between prostate cancer and the SNPs with low minor
allele frequency (Table 5) are likely to be false positive
associations given the small number of prostate cancer
cases in our sample. Third, the 100K Affymetrix GeneChip
provides limited coverage of the genome; many of our a
priori candidate genes did not have any SNP coverage on
the chip and coverage of some candidate genes that were
present on the chip was suboptimal. Importantly, the rep-
licated risk SNP, rs1447295, for prostate cancer [5] was
not included on the chip. NHLBI has committed funds for
a 550 K genome-wide scan on all FHS participants. This
will enable us to confirm our initial 100K SNP associa-
tions in a larger sample with a greater number of cancer
cases and with denser coverage of the genome. We did not
examine epistasis or gene-environment interactions
which may modify the associations noted in this study.
Lastly, most of our associations are likely to be due to
chance. Replication studies are needed to determine if any
of the results we report are indicative of true associations.
It is important that our data be used in conjunction with
data from other samples given the high probability of
false positive associations.
Conclusion
In summary, the untargeted genome-wide approach to
detect genetic associations for cancer traits provides an
opportunity to identify novel biologic pathways related to
cancer occurrence and to direct future study of candidate
genes that hold the most promise for relevance to cancer
risk in humans. Enhancing our understanding of the
Table 4: SNPs in the Chromosome 8q24 region Associated with Prostate Cancer:GEE or FBAT p-value < 0.01
SNP Physical Position Distance from 
reported marker
MAF GEE p-value FBAT p-value
rs7001069 128179828 -253268 0.0188 3.0 × 10-5 0.39322
rs10505483 128194377 -238719 0.0223 4.0 × 10-5 0.32697
rs1562871 128470954 37858 0.1696 0.16618 0.00328
rs10505474 128486686 53590 0.406 0.00995 0.0121
rs10505506 129114473 681377 0.3275 0.00829 0.92941
Table 5: Prostate Cancer SNP Associations Common to Both CGEMS Top 500 Ranked SNPs and FHS 100K SNPs
CGEMS Phase 1a FHS 100K
DBSNP_ID Chr Physical Position CGEMS p-value CGEMS 
Rank
100K SNP Physical
Position
GEE p-value FBAT p-value MAF Nearest 
Gene
Minor Allele Frequency ≥10%
rs3017183 18 51,319,241 0.00024100 85 rs3794889 51,212,935 0.017 0.799 0.224 TCF4
rs3017183 18 51,319,241 0.00024100 85 rs4801149 51,214,227 0.044 0.983 0.221 TCF4
rs2253319 21 35,109,916 0.00041100 137 rs2834645 35,109,556 0.009 0.293 0.206 RUNX1
rs392715 16 24,023,323 0.00041800 141 rs10492797 24,122,453 0.036 0.407 0.175 PRKCB1
rs10256504 7 3,516,796 0.00092200 295 rs4418248 3,194,181 1.8 × 10-4 0.056 0.109 SDK1
rs6102912 20 40,636,349 0.00111000 350 rs986831 40,594,892 0.009 0.094 0.407 PTPRT
rs4782742 16 81,573,151 0.00127400 395 rs254315 82,313,913 7.1 × 10-4 0.011 0.141 CDH13
rs2371438 2 212,791,037 0.00128500 401 rs10497958 212,771,465 0.055 0.047 0.164 ERBB4
rs6577648 8 135,555,688 0.00144900 445 rs10505624 135,607,862 4.9 × 10-4 0.007 0.147 ZFAT1
rs9327886 5 102,931,646 0.00154600 468 rs10515347 102,950,833 0.006 0.062 0.354 NUDT12
rs6555491 5 7,799,792 0.00158700 478 rs10512920 7,455,561 0.009 0.647 0.244 ADCY2
Minor Allele Frequency <10%
rs38276 7 14,078,240 0.00055700 181 rs10486031 14,258,703 1.7 × 10-5 0.759 0.032 DGKB
rs216666 2 80,745,015 0.00057000 184 rs10520247 79,693,452 2.8 × 10-5 0.240 0.065 CTNNA2
rs216666 2 80,745,015 0.00057000 184 rs10520246 79,693,324 1.5 × 10-4 0.198 0.050 CTNNA2
rs1261256 5 22,490,853 0.00060200 193 rs10520880 22,634,003 8.5 × 10-5 0.356 0.065 CDH12
rs7610584 3 171,635,885 0.00061900 196 rs10513681 171,624,010 7.8 × 10-7 0.402 0.025 CLDN11
rs7329659 13 97,872,564 0.00064700 209 rs7989050 97,680,299 6.0 × 10-6 0.258 0.014 FARP1
rs208354 7 2,554,104 0.00065000 211 rs10487577 2,583,719 2.0 × 10-7 N/A 0.012 GNA12
rs3751832 16 77,771,773 0.00079900 257 rs10514443 77,353,386 9.3 × 10-4 N/A 0.008 WWOX
CGEMS = Cancer Genetics Markers of Susceptibility; MAF = minor allele frequency; N/A= not available, less than 10 informative families for FBATPage 7 of 10
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BMC Medical Genetics 2007, 8(Suppl 1):S6 http://www.biomedcentral.com/1471-2350/8/S1/S6mechanisms responsible for cancer susceptibility may in
turn identify novel strategies for early detection, preven-
tion, and treatment of breast and prostate cancers. These
data serve as a resource for replication in other popula-
tion-based samples.
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